Increased S(-)-apomorphine-induced vacuous chewing and attenuated effect of chronic haloperidol treatment in streptozotocin-induced diabetic rat.
The incidence of S(-)-apomorphine-induced vacuous chewing movements (VCMs) as a model for tardive dyskinesia was investigated in streptozotocin (STZ)-induced diabetic rats. A single dose of STZ (65 mg/kg, intravenously) caused a diabetic state (hyperglycemia, 480-490 vs. 116-118 mg/dl in naive rats). S(-)-apomorphine (250 micrograms/kg, subcutaneously)-induced VCMs were significantly intensified in diabetic rats which had received STZ 9 weeks previously. The enhancement of VCMs was also observed in nondiabetic rats which received subsequent treatment with depot haloperidol (4 mg/kg, intramuscularly, once a week, every week for 4 weeks) followed by a 2-week washout period. The ability of haloperidol to enhance VCMs was attenuated in diabetic rats. The implications of these results in relation to altered neurotransmissions in STZ-induced diabetes are discussed.
Sumiyoshi
T
T
Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
Ichikawa
J
J
Meltzer
H Y
HY
D000704:Analysis of Variance; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D006220:Haloperidol; D001058:Apomorphine